Contribute Try STAT+ Today

Hello, everyone, and how are you today? We are doing just fine, thank you. Clear, blue skies and comfortable temperatures are enveloping the Pharmalot campus, where our short person is, once again, hunched over a laptop in pursuit of some learning, while our official mascot is being walked about the neighborhood. This gives us time to fire up the coffee kettle and brew a cup of stimulation — our choice today is coconut. We have also gathered a few items of interest to help you get started this morning. We hope all goes well today and that you conquer the world. Meanwhile, do stay in touch. We enjoy your tips and feedback. …

A Food and Drug Administration advisory committee is meeting Thursday to consider whether the agency should authorize emergency use of the Covid-19 vaccine developed by Pfizer (PFE) and BioNTech (BNTX) that appeared to be highly efficacious in a Phase 3 clinical trial, STAT notes. If the panel recommends emergency use, and if the FDA follows the advice, the rollout of Covid-19 vaccine will begin within a few days in the U.S. Earlier this week, the U.K. started using the vaccine and Canada’s drug regulator approved emergency use. (Live updates will be here.)

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.